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Abstract.
Background: The most advanced disease-modifying therapies (DMTs) in development for Huntington’s disease (HD) require
intrathecal (IT) administration, which may create or exacerbate bottlenecks in resource capacity.
Objective: To understand the readiness of healthcare systems for intrathecally administered HD DMTs in terms of resource
capacity dynamics and implications for patients’ access to treatment.
Methods: Forty HD centres across 12 countries were included. Qualitative and quantitative data on current capacity in
HD centres and anticipated capacity needs following availability of a DMT were gathered via interviews with healthcare
professionals (HCPs). Data modelling was used to estimate the current capacity gap in HD centres.
Results: From interviews with 218 HCPs, 25% of HD centres are estimated to have the three components required for IT
administration (proceduralists, nurses and facilities). On average, 114 patients per centre per year are anticipated to receive
intrathecally administered DMTs in the future. At current capacity, six of the sampled centres are estimated to be able to
deliver DMTs to all the anticipated patients based on current resources. The estimated waiting time for IT administration at
current capacity will average 60 months (5 years) by the second year after DMT availability.
Conclusion: Additional resources are needed in HD centres for future DMTs to be accessible to all anticipated patients.
Timely collaboration by the HD community will be needed to address capacity gaps. Healthcare policymakers and payers
will need to address costs and navigate challenges arising from country- or region-specific healthcare delivery schemes.
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and services, health resources, health services accessibility
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INTRODUCTION
Management of Huntington’s disease (HD) is com-
plex, requires multidisciplinary care and is based
on pharmacological and non-pharmacological symp-
tomatic treatments [1–4]. As there are no treatments
which can slow, halt or reverse disease progression
[5, 6], HD management aims to maximise function
and optimise patients’ quality of life [7]. Over the past
decade, major focus has been placed on the develop-
ment of disease-modifying therapies (DMTs) for HD
[5]. One of the main therapeutic approaches under
investigation to slow or stop HD progression is the
lowering of mutant huntingtin protein (mHTT) pro-
duction [6, 8]. The most advanced DMTs in clinical
development for HD are antisense oligonucleotides
(ASOs) [8].
ASOs are generally too large to permeate the
blood–brain barrier [9]. Intrathecal (IT) administra-
tion of ASOs into the cerebrospinal fluid (CSF) [9,
10] via lumbar puncture [10] allows distribution to
the central nervous system [11]. IT administration
is a feasible and generally well-tolerated procedure,
with established monitoring and management for
side effects such as headache and CSF leakage [12].
Practical considerations for performing the IT admin-
istration procedure in clinical settings include the
availability of healthcare professionals (HCPs) with
adequate expertise, the requirement for support staff,
the monitoring of patients, and the availability of
suitable facilities.
The intrathecally administered ASO, nusinersen
(Spinraza™) [13] was the first DMT approved for the
treatment of spinal muscular atrophy (SMA) [14].
Lessons from challenges faced by nusinersen treat-
ment in the real world could provide valuable insights
into the capacity constraints and logistics associated
with introducing IT administration procedures into
healthcare systems. Serious capacity challenges were
evidenced in the nusinersen Global Expanded Access
Program for individuals with infantile-onset SMA,
which experienced delays in programme participa-
tion due to reconfiguration and/or building of capacity
in treatment sites [15].
For HD, experience of IT administration derives
primarily from the global clinical development pro-
gramme of the HTT-targeting ASO tominersen,
including GENERATION HD1 (NCT03761849), the
ongoing Phase III study of tominersen in patients
with manifest HD as well as other ASO programmes
that have not yet been published. Given that clini-
cal guidelines for the IT administration of HD DMTs
are not yet defined, the GENERATION HD1 clinical
protocol currently provides the most relevant infor-
mation on the procedure in the context of HD.
Although the IT administration procedure will only
be one part of HD treatment, it may become a limiting
step for resource capacity. With the potential avail-
ability of future HD DMTs, it is important to assess
how this may result in capacity limitations and adjust-
ments to multidisciplinary care. Given the impact of
capacity limitations on patient and healthcare system
outcomes, proactive capacity planning is required to
improve patients’ access to upcoming therapies.
This study aims to understand the readiness of
healthcare systems for upcoming intrathecally adm-
inistered HD DMTs, in terms of possible resource
capacity dynamics. This study will focus on resources
currently available in HD centres for the IT adminis-
tration procedure and the scale of changes needed to
address potential capacity limitations.
MATERIALS AND METHODS
Study design
Multi-source data collection was used to estimate
the current and needed capacity for HD centres to
manage patients in a future with intrathecally admin-
istered DMTs. Data were also gathered on the current
resource availability of HD centres to perform follow-
up consultations. Qualitative and quantitative data
on HD centre capacity, local HD therapeutic envi-
ronments and the IT administration procedure were
gathered via interviews with therapy area experts
(TAEs) (identified by F. Hoffmann-La Roche Ltd.
affiliates) including neurologists who had partici-
pated in HD clinical trials involving intrathecally
administered DMTs, patient advocacy group (PAG)
representatives and HCPs who were employed at HD
centres. All interviews were anonymised, conducted
in accordance with the local regulations of each coun-
try and used standardised discussion guides to ensure
consistency of quantitative and qualitative data. All
respondents were compensated at local Fair Market
Value rates defined by F. Hoffmann-La Roche Ltd.
Data modelling was used to generate quantitative data
on the capacity gaps in HD centres for intrathecally
administered HD DMTs. The steps and resources
needed for the IT administration of HD DMTs were
based on the protocol for GENERATION HD1. This
study assumes a scenario whereby all patients fulfill-
ing the GENERATION HD1 inclusion criteria will
benefit from HD DMT treatment, rather than patients
at a specific stage of HD.
M. Guttman et al. / Capacity Limitations in Huntington’s Disease 305
Twelve countries were selected for inclusion in
the study based on consideration of HD prevalence,
on seeking diversity of the structure (centralised or
decentralised) and maturity of the healthcare system.
This study aimed to recruit 40 HD centres in total,
assessing at least one HD centre for each of the
identified countries: Australia, Brazil, Canada, Col-
ombia, Egypt, France, Germany, Italy, Mexico,
Spain, Sweden and the United Kingdom. The United
States did not participate in this assessment because
they were included in a separate study. Data from
three sources were used to develop the prelimi-
nary list of HD centres: the European Huntington’s
Disease Network (http://www.ehdn.org), to iden-
tify centres participating in Enroll-HD; Orphanet
(http://www.orpha.net), to identify ‘expert centres’;
and http://www.clinicaltrials.gov to identify centres
participating in clinical trials.
The preliminary list of 201 HD centres was vali-
dated by interviews with one or two TAEs and PAG
representatives per country. For countries in which
only one HD centre was drafted on the preliminary
list, no TAEs or PAG representatives were inter-
viewed and data were collected directly from the HD
centre. Each centre was given the opportunity to opt
in to the study, and the first 40 centres to respond were
recruited. HCPs in each HD centre were approached
for interview, on account of their routine involvement
in HD care and/or IT administration procedures. All
interviews were based on a standardised qualitative
discussion guide.
HD centres were defined as hospitals or academic
institutions in which HD clinics are based. HD clinics
were defined as the combination of resources cur-
rently dedicated to HD treatment within HD centres,
e.g., one neurologist and one nurse dedicated to HD
treatment 1 day per week, although resource combi-
nations may vary between different HD clinics.
TAE and PAG representative interviews
TAEs and PAG representatives were interviewed
on HD management and treatment in their respec-
tive countries. These preliminary interviews aimed
to gather country-level information to support the
development of hypotheses on capacity issues in a
future with intrathecally administered HD DMTs.
These hypotheses were later reflected in the discus-
sion guides for HCP interviews.
Each interview discussed the following topics:
local epidemiology of HD; patient distribution in rela-
tion to HD centres; and care pathway from initial
presentation through to ongoing management. TAEs
were also asked about potential capacity-related
issues for the IT administration procedure in trial sites
and non-trial sites.
HCP interviews
Interviews were conducted with the following
HCPs to gather centre-level data: specialist HD neu-
rologists (who were given the opportunity to refer
additional HCPs to the study during interview), other
physicians anticipated to be potentially involved
in the IT administration of HD DMTs (non-HD
neurologists and oncologists), nurses, pharmacists,
anaesthesiologists, interventional radiologists (IRs),
budget administrators and administration staff. Pro-
ceduralists have been defined as HD neurologists,
non-HD neurologists, anaesthesiologists and IRs.
The objectives for each type of HCP interview are
outlined in the Supplementary Material.
Data were collected on the current patient popula-
tions being managed at each HD centre; the available
resources currently being dedicated to the manage-
ment of HD; and the resources available for disease
management if an intrathecally administered HD
DMT were available the following day. The will-
ingness of HCPs to carry out the IT administration
procedure was also taken into consideration when
estimating the resource capacity currently available.
Data modelling
A linear quantitative model was developed to
estimate the capacity gap in HD centres for the man-
agement of HD, including the ability to perform
IT administration procedures for HD DMTs in the
future. The capacity gap per HD centre (Fig. 1) was
estimated using HCP interview data, assumptions
based on the GENERATION HD1 protocol (Table 1),




In total, 218 HCPs opted in to the study for
interview. The number of HCPs interviewed per
type were: 70 HD neurologists, 18 HD nurses, 20
anaesthesiologists/IRs, 90 other physicians from the
General Neurology and Oncology departments, 11
administrative staff and 9 pharmacists.
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Fig. 1. Data modelling methodology. Data modelling was performed in three main steps. The estimated resources needed in HD centres to
perform the IT administration of an HD DMT per year was calculated, while accounting for the number of patients who are anticipated to
need treatment in the future. The resources currently available in HD centres for the procedure were then estimated. Calculations from Steps
1 and 2 were used to quantify the current estimated capacity gap in HD centres for the IT administration procedure. DMT, disease-modifying
therapy; HCP, healthcare professional; HD, Huntington’s disease; IT, intrathecal; TAEs, therapy area experts.
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Table 1
Assumptions on the resources needed to intrathecally administer an HD DMT per patient,
based on the GENERATION HD1 protocol
Resource Assumptions based on the GENERATION HD1
protocol (time calculated as FTE)
Proceduralist x1 60 minutes of total proceduralist time needed per procedure:
• 15 minutes – patient preparation
• 40 minutes – collection of CSF samples for analysis
• 5 minutes – IT bolus injection
Nurse x2 155 minutes of total nurse time needed per procedure:
• 10 minutes – patient check-in and education
• 10 minutes – facility preparation
• 15 minutes – patient preparation
• 40 minutes – CSF collection (2 nurses, 40 minutes per nurse)
• 5 minutes – IT bolus injection (2 nurses, 5 minutes per nurse)
• 30 minutes – patient mobilisation and monitoring
Facilities to perform 70 minutes of chair/bed occupancy needed per procedure:
the procedure x1 • 10 minutes – facility preparation
• 15 minutes – patient preparation
• 40 minutes – CSF collection
• 5 minutes – IT bolus injection
CSF, cerebrospinal fluid; DMT, disease-modifying therapy; FTE, full-time equivalent; HD, Huntington’s
disease; IT, intrathecal.
The recruitment target of 40 HD centres was
reached. The number of HD centres recruited per
country were: Germany (8), UK (6), Italy (6), France
(5), Canada (5), Brazil (4), Sweden (1), Spain (1),
Australia (1), Egypt (1), Colombia (1), Mexico (1).
Currently available resources and additional
resources needed for the IT administration
procedure
Interviews with HCPs revealed that they currently
do not dedicate their time exclusively to HD manage-
ment. On average, sampled HD neurologists allocate
1.25 days per week to HD clinics (0.25 full-time
equivalents [FTEs]), while nurses allocate 0.15 FTEs.
Based on data modelling and the HD centres’
patient population data gathered from HCP inter-
views, an estimated average of 114 patients per
centre per year are anticipated to receive intrathecally
administered HD DMTs in the future. The estimated
resources needed to deliver intrathecally adminis-
tered HD DMTs for 114 patients per centre are shown
in Fig. 2. These FTEs translate to: 2 days per week
of a neurologist/proceduralist (3 times the number
of currently available resources); 2 days per week of
two nurses (7 times the number of currently avail-
able resources); and 2 days per week of facilities
with a suitable bed (2 times the number of currently
available resources).
According to interviews, the three components
assumed to be required for the IT administration
procedure (proceduralists, nurses and facilities) are
Fig. 2. Currently available resources and additional resources
needed to perform IT administration procedures for all patients
anticipated to receive an HD DMT. The estimated FTEs needed
per resource, per HD centre, to perform the procedure on all
anticipated patients each year are shown at the top of each bar.
Current resources estimated to be available for the procedure are
shown alongside the additional resources needed for the proce-
dure. Measured in FTEs, averaged across all sampled HD centres.
DMT, disease-modifying therapy; FTEs, full-time equivalents;
HD, Huntington’s disease; IT, intrathecal.
currently available in 25% of the sampled HD centres.
Half of the HD centres lack either nurses or facilities,
and 25% lack both nurses and facilities.
Data modelling showed that 6 HD centres (15%)
are estimated to be able to deliver intrathecally admin-
istered HD DMTs to 100% of patients anticipated
to receive treatment. Fewer than 50% of anticipated
patients in 25 HD centres (62%) would have access
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Fig. 3. Ability of sampled HD centres to perform IT procedures for all patients anticipated to receive an HD DMT. Dark bars show the
sampled HD centres which currently have the required amount of resources to perform the procedure for all anticipated patients in a year.
Light bars show the percentage of anticipated patients the other sampled HD centres can treat via the procedure, considering the resources
estimated to be currently available. DMT, disease-modifying therapy; HD, Huntington’s disease; IT, intrathecal.
to intrathecally administered HD DMTs and < 30% of
anticipated patients would have access to HD DMTs
in 18 HD centres (45%) (Fig. 3).
Based on interview responses, the model estimates
an average waiting time of 60 months (5 years) for IT
administration procedures will emerge by the second
year after HD DMT availability.
Skills and willingness of HCPs to perform the IT
administration procedure
According to HCP interviews, 49% of sampled
HD neurologists have had recent experience with the
IT administration procedure, although all are famil-
iar with lumbar punctures. On average, an estimated
60–70% of HD neurologists in the assessed HD cen-
tres are willing to perform the procedure.
HD neurologists and nurses believe that 90% of
nurses have sufficient general skills to assist in the IT
administration procedure. It is estimated that 80% of
nurses in the assessed HD centres are willing to assist
with the procedure.
IRs are generally skilled in the IT administration
procedure. However, they have low availability due
to high occupancy with other duties and are cur-
rently not involved in HD management. IR teams are
small-to-medium in size, with an average of six IRs
per HD centre. Interviews with IRs suggest that they
are generally interested in performing the procedure.
However, a low response rate (<5%) from IRs was
noted during the recruitment phase of this study.
Anaesthesiologists are also skilled in the IT admin-
istration procedure but are highly occupied with other
duties, with limited involvement in HD management.
Anaesthesiologist teams are medium-to-large in size,
with 38 anaesthesiologists on average per HD centre.
Interviews suggest that anaesthesiologists are gener-
ally interested in performing the procedure and can
increase their working hours to create capacity, alth-
ough incremental financial incentives may be
required.
The skills and willingness of other physicians
to perform the IT administration procedure for HD
DMTs are discussed in the Supplementary Material.
DISCUSSION
As there are currently no intrathecally adminis-
tered DMTs approved for HD, resources and capacity
for the IT administration procedure have not been
required in HD centres. However, given the HD
DMTs in clinical development, it is expected that
resources and capacity planning will be needed to
accommodate these therapies. This study has high-
lighted the potential scale of the changes needed to
address the capacity gap and the associated urgency
if extended waiting lists are to be avoided. Immediate
discussions between policymakers and the HD com-
munity, including providers, HD clinicians, PAGs and
families are needed to avoid delays in patients’ access
to HD DMTs in the future.
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IT administration is anticipated to be the largest
bottleneck for HD centres in the surveyed countries.
Specifically, findings suggest that additional proce-
duralists, nurses and facilities will be needed for
the procedure to be integrated into HD treatment
after intrathecally administered HD DMTs receive
approval from regulatory authorities.
While the relative increase in resources needed to
perform the procedure appears high, in absolute terms
(e.g., 0.36 FTE for proceduralists and 0.92 FTE for
nurses) they are achievable. Furthermore, most HD
neurologists and nurses in the sampled HD centres
expressed willingness to perform the procedure.
HCP training may be necessary depending on
HD centres’ resource needs and each HCP’s per-
sonal roles, skills and experience. Certain HCPs may
need training on the HD therapy area, while others
recruited for the proceduralist role may need train-
ing from experienced proceduralists due to lack of
practical experience.
The development of a financial plan by current
healthcare policymakers and payers to address the
costs associated with delivering intrathecally admin-
istered HD DMTs will be crucial. Although the costs
of physicians will likely be covered by insurance
plans and universal healthcare coverage in different
countries, costs associated with facilities and HCPs
such as nursing staff, administrative staff, and phar-
macists present a gap in the current healthcare system
that requires long-term planning.
Complexities arising from country- and region-
specific healthcare delivery models should also be
anticipated. For instance, some institutions may have
adequate resources for the procedure but are cur-
rently funded solely for research initiatives. Funding
specific to clinical care will be necessary for these
institutions to deliver the IT administration procedure
in a clinical capacity.
Limitations
This study was an initial pilot designed to gain
directional insights into the readiness of healthcare
systems for upcoming intrathecally administered HD
DMTs, in terms of resource capacity. As this study
was designed as a market research survey of the HD
environment, it does not provide a definitive mapping
of the topic and contains expected limitations in study
design.
Assumptions were made on the resources required
for the IT administration procedure, based on the
GENERATION HD1 protocol. These assumptions
may be different to future real-world administra-
tion of HD DMTs, such as the supportive use of
spinal ultrasounds [16] (Supplementary Material)
and variations across geographies. The time required
for the procedure was estimated based on experi-
ence from GENERATION HD1 and may be different
after intrathecally administered HD DMT therapy
is approved. Capacity in HD centres was calculated
based on resources available for the patient load at the
time of the study, including resources that were not
dedicated to HD. Future allocation of resources and
patient load may differ if appropriate funding is allo-
cated to fulfil the anticipated need for HD DMTs. The
number of patients anticipated to receive DMTs in the
future may also change, as the estimates used in this
study were based on GENERATION HD1 inclusion
criteria and HD neurologist interviews.
Inclusion of HD centres and countries in the study
sample was not based on statistical considerations,
and the number of HD centres involved in this study
was relatively limited due to the targeted recruitment
of 40 HD centres. Two hundred and one HD centres
were approached for study recruitment, to circumvent
the anticipated low response rate and unwillingness
to participate in the study. The topic of capacity lim-
itations in future HD treatment may not have been
perceived as a priority for HD centres who were
experiencing minimal resourcing concerns at time
of recruitment. In contrast, other HD centres may
not have had sufficient capacity to dedicate time to
study participation. Although this study was con-
ducted across 12 countries, the results may not be
representative of the assessed locations or be applica-
ble to non-assessed countries. However, the assessed
centres are a starting point in understanding capac-
ity limitations and provide cross-sectional insights
across the surveyed countries.
Potential capacity available in non-HD centres was
initially assessed but was omitted from this publica-
tion due to limited sample size. Non-HD centres were
defined as centres not involved in HD management
at the time of this study, but which could have capac-
ity for IT administration in the future (e.g., General
Neurology or Oncology centres).
Biases in data collection are implicit in interview-
based studies despite the strategies implemented to
mitigate them. For instance, the low response rate
from IRs indicates potential bias in the interview sam-
ple, whereby IRs who did not opt in to the study may
have limited interest in working with HD DMTs in
the future. The number of HCPs interviewed within
each HD centre was also limited.
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A final caveat is that this study assesses current
capacity and does not assess potential capacity con-
straints in HD centres at the time of future DMT
availability, nor does this study aim to suggest solu-
tions to potential capacity constraints.
Recommendations for future studies
As the HD community prepares for intrathecally
administered HD DMTs, the capacity of HD centres
should be reassessed, and applicable solutions will
need to be developed to address capacity gaps. Future
studies can incorporate larger sample sizes (e.g.,
HCPs, HD centres, more countries, patients outside
of HD centres); assess the impact of healthcare sys-
tem design on HD centres’ ability to address capacity
gaps; explore the potential of sourcing capacity from
non-HD centres; analyse interview data in combina-
tion with HD centre databases; and map costs for the
procedure across different geographies.
Given the emergence of the IT administration pro-
cedure as a future step in the treatment of neurological
diseases, including but not limited to HD, capacity-
related analyses should be conducted based on
differing resource requirement assumptions. These
analyses may vary from current assumptions derived
from the GENERATION HD1 protocol and will sup-
port the future development of guidelines for the
procedure.
Although this study focuses on capacity limitations
for the IT administration procedure, HD treatment
consists of multiple components. Future studies will
need to assess the readiness of healthcare systems
to deliver all aspects of HD treatment, ahead of HD
DMT availability. Factors such as drug efficacy and
population data are also important, which will inform
on the magnitude of benefit and identify patient pop-
ulations suited for treatment.
CONCLUSIONS
Healthcare systems need time to gain awareness
and ascertain how to perform high-quality IT admin-
istration procedures safely and at scale. The HD
community needs to become aware of current capac-
ity constraints as soon as possible and collaborate
on international, national and subnational levels to
address these capacity gaps for future HD DMTs. By
working proactively and delivering appropriate solu-
tions in a timely manner, access to upcoming HD
DMTs will be facilitated and more readily available
to patients.
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